Human TRIM22 knockout A549 cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
TRIM22 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3 and 8 bp deletion in exon3.
View Alternative Names
50 kDa stimulated trans acting factor, GPSTAF50, RING finger protein 94, RNF94, STAF50, Staf 50, Stimulated Trans Acting Factor (homolog of Mouse Rpt 1 gene), Stimulated trans acting factor (50 kDa), TTRIM22RIM22, Tripartite binding motif 22, Tripartite motif containing protein 22
- Sanger seq
Unknown
Sanger Sequencing - Human TRIM22 knockout A549 cell lysate (AB259206)
Allele-2 : 1 bp insertion in exon3
- Sanger seq
Unknown
Sanger Sequencing - Human TRIM22 knockout A549 cell lysate (AB259206)
Allele-1 : 8 bp deletion in exon3
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
TRIM22 plays a significant role in innate immunity influencing the antiviral response. As an E3 ubiquitin ligase it facilitates the ubiquitination and degradation of host proteins that are involved in viral replication processes. TRIM22 does not generally function in a protein complex but it interacts with other proteins in a cellular context. This interaction enhances the cellular response against viral infections by disrupting viral components and inhibiting viral replication.
Pathways
TRIM22 is involved in the IFN (interferon) signaling pathway which is essential for the immune response against pathogens. In this pathway TRIM22 interacts with proteins like IFNAR1 and STAT1 acting as a mediator of antiviral activities. It also participates in the ubiquitin-proteasome system aiding in the regulation of protein turnover within the cell. These pathways demonstrate the broad scope of TRIM22 in maintaining cellular homeostasis and responding to external immune challenges.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male
Complementary Products
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com